Valeant Pharmaceuticals International Inc (VRX.TO)
16 Mar 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|61||2016||Chairman of the Board, Chief Executive Officer|
|61||2016||Chief Financial Officer, Executive Vice President|
|52||2016||Executive Vice President, General Counsel|
|55||2016||Executive Vice President, Company Group Chairman, International|
|50||2017||Executive Vice President, Company Group Chairman, Dermatology|
- BRIEF-Valeant Receives Health Canada Approval Of Siliq (Brodalumab) For Moderate-To-Severe Plaque Psoriasis
- BRIEF-Valeant Announces Launch Of Private Offering Of Senior Notes
- BRIEF-Valeant And One Of Its Subsidiaries Commence Cash Tender Offers For Up To $1,250,000,000 Outstanding Principal Amount
- BRIEF-Valeant Says For 2018, CEO Joseph Papa Will Receive Long-Term Incentive Award With Aggregate Value Of $10 Mln
- BRIEF-Valeant Files For Potential Mixed Shelf Offering Size Not Disclosed - SEC Filing